

Today's Notes:

1. Senesco Makes Progress

1. Senesco (SNT AMEX)

As we have suggested Senesco technologies is now "in the clinic" with its first cancer therapy SNSO1-T. The tests at the Mayo Clinic are underway as I write this Morning Note. This test is a Phase 1B /2A safety test of SNT's multiple myeloma therapy but we will have some indication of the success of the therapy as the dosage is increased.

The company also announced today that it had run tests on two other cancers human mantle cell and diffuse large B-cell lymphomas in the mouse model. Les Browne Senesco's CEO said, "The Company has demonstrated in the laboratory that SNSO1-T can significantly inhibit the growth of both human mantle cell and diffuse large B-cell lymphomas in a dose dependent manner in mouse xenograft models."

This pre-clinical tests of tests has extended the reach of the company's cancer therapy and provided indications that factor 5A therapy might indeed answer a lot of cancer questions. Potential additional effectiveness was observed from in vitro studies in which SNSO1-T was combined with other approved myeloma drugs.

"We believe we have shown that certain myeloma drugs can be up to 40 times more potent in vitro when used in combination with SNSO1-T," stated Leslie J. Browne, Ph.D., President and CEO of Senesco. ***"Together these results further reinforce the significance of our target, eIF5A, and will guide us in designing our future clinical studies."***

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis.

In test tube studies (in vitro) the therapy has been successful against every form of human cancer cells tested. In the mouse model SNSO1-T has reduced tumor load and weight by up to 90 to 95%. One mouse was found to go into remission.

In the United States there are approximately 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNSO1-T, the Company's lead drug candidate for treatment of multiple myeloma.




Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications treating certain inflammatory and ischemic diseases. The Company has initiated a clinical study in multiple myeloma with its lead therapeutic candidate SNSO1-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners' products. The company has about \$2.5 million cash on the balance sheet. We own shares of Senesco Technologies.

We will formerly introduce the Discovery Investing Scoreboard in January (23rd) at the Cambridge House symposium in Vancouver. In the meantime we will be seeking individuals with an interest in utilizing the software to rank companies of interest as we create a global Crowd Data base of discovery opportunities. See the You Tube video and DiS Ten Point grid below.

<http://youtu.be/Uo0FjTmkMP8>

THE 10-POINT DISCOVERY GRID



Company Diversification

- Size of asset portfolio
- Potential for monetization
- Quality of strategic focus across assets

Investor Sentiment

- Patience of investors
- Belief in company prospects

Company's Stakeholder Relations

- Accessibility of management
- Prompt & reliable communications
- Relations with critical outside

Financial Soundness/ Sustainability/Dilution Management

- Cash on hand
- Absence of toxic financing
- Capital required to reach major milestones
- Production potential, offtake agreements

Management/Board

- Insider buying
- Significant ownership
- Demonstrated track record of success

World Class Assets/IP/ Technology

- Asset/IP/Technology production economics
- Global supply vs. demand
- Required infrastructure availability
- Expansion potential
- Simplicity/complexity of production processes

Asset Technology Potential/ Immediacy

- Immediacy of product availability
- Importance of product to future needs/desires

Cycle and Catalyst Identification

- Identification with super-cycle trends
- Identification with Quality of Life cycle trends
- Milestone catalyst anticipation
- Position relative to mystery/history cycle

Contrarianness of Assets

- Acquisition costs relative to value

Percent Project Ownership

- Control of project destiny

The material herein is for informational purposes only and is not intended to and does not constitute the rendering of investment advice or the solicitation of an offer to buy securities. The foregoing discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The Act). In particular when used in the preceding discussion the words "plan," confident that, believe, scheduled, expect, or intend to, and similar conditional expressions are intended to identify forward-looking statements subject to the safe harbor created by the ACT. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward looking statements. Such risks and uncertainties include, but are not limited to future events and financial performance of the company which are inherently uncertain and actual events and / or results may differ materially. In addition we may review investments that are not registered in the U.S. We own shares in Senesco Technologies. We cannot attest to nor certify the correctness of any information in this note. Please consult your financial advisor and perform your own due diligence before considering any companies mentioned in this informational bulletin.